miR-365a-5p suppresses gefitinib resistance in non-small-cell lung cancer through targeting PELI3

被引：7
|
作者：
Li, Fannian [1 ]
Li, Haitao [2 ]
Li, Shuai [2 ]
Lv, Baolei [3 ]
Shi, Junjie [4 ]
Yan, Hongjiang [5 ]
Zhang, Helin [5 ]
He, Yuzheng [5 ]
机构：
[1] First Hosp XingTai, Dept Thorac Surg, 376 Shunde Rd, Xingtai 054001, Hebei, Peoples R China
[2] Hebei Med Univ, Dept Pulm & Crit Care Med, Hosp 2, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China
[3] First Hosp Shijiazhuang, Dept Thorac Surg, 36 Fanxi Rd, Shijiazhuang 050011, Hebei, Peoples R China
[4] Handan First Hosp, Dept Thorac Surg, 25 CongTai Rd, Handan 056002, Peoples R China
[5] Hebei Med Univ, Dept Thorac Surg, Hosp 2, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China
来源：
PHARMACOGENOMICS | 2020年 / 21卷 / 11期
关键词：
gefitinib resistance; miR-365a-5p; non-small-cell lung cancer; PELI3;
D O I：
10.2217/pgs-2020-0006
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim: Demonstrate the function of dysregulated miR-365a-5p-PELI3 signaling axis in the generation of gefitinib resistance during treatment for non-small-cell lung cancer (NSCLC). Patients & methods: All the NSCLC patients who participated in this research were recruited from the Second Hospital of Hebei Medical University. PC9 cells and PC9GR cells were cultured for in vitro experiments. Results: Patients who were primary resistant to EGFR-tyrosine kinase inhibitor had lower miR-365a-5p levels. MiR-365a-5p directly targeted PELI3 mRNA. MiR-365a-5p overexpression enhanced the function of gefitinib in inhibiting cell viability. Tumor growth was suppressed through miR-365a-5p in nude mice. Conclusion: Dysregulated miR-365a-5p-PELI3 signaling axis triggered the generation of gefitinib resistance in NSCLC.
引用
收藏
页码：771 / 783
页数：13
相关论文
共 50 条
  • [1] PELI3 mediates pro-tumor actions of down-regulated miR-365a-5p in non-small cell lung cancer
    He, Yuzheng
    Shi, Yantao
    Liu, Ruilin
    Wang, Zhichao
    Wang, Baohua
    Li, Shujun
    Zhang, Helin
    [J]. BIOLOGICAL RESEARCH, 2019, 52 (1) : 24
  • [2] PELI3 mediates pro-tumor actions of down-regulated miR-365a-5p in non-small cell lung cancer
    Yuzheng He
    Yantao Shi
    Ruilin Liu
    Zhichao Wang
    Baohua Wang
    Shujun Li
    Helin Zhang
    [J]. Biological Research, 52
  • [3] FTO promotes gefitinib-resistance by enhancing PELI3 expression and autophagy in non-small cell lung cancer
    He, Yu-Zheng
    Li, Xiao-Ning
    Li, Hai-Tao
    Bai, Xian-Hua
    Liu, Yan-Chao
    Li, Fan-Nian
    Lv, Bao-Lei
    Qi, Tian-Jie
    Zhao, Xiu-Min
    Li, Shuai
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2024, 87
  • [4] miR-147a suppresses the metastasis of non-small-cell lung cancer by targeting CCL5
    Lu, Yan
    Luan, Xiao Rong
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019,
  • [5] miR-145-5p Modulates Gefitinib Resistance by Targeting NRAS and MEST in Non-Small Cell Lung Cancer
    Yu, Chuigong
    Li, Bingqing
    Wang, Jinghao
    Zhang, Ziyue
    Li, Shengjing
    Lei, Shixiong
    Wang, Qinhao
    [J]. ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2021, 51 (05): : 625 - 637
  • [6] Long Non-coding RNA MIAT Mediates Non-small Cell Lung Cancer Development Through Regulating the miR-128-3p/PELI3 Axis
    Fannian Li
    Haitao Li
    Shuai Li
    Baolei Lv
    Junjie Shi
    Hongjiang Yan
    Helin Zhang
    Yuzheng He
    [J]. Biochemical Genetics, 2020, 58 : 867 - 882
  • [7] MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5
    Li, Qing
    Wang, Yueming
    He, Jingdong
    [J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (07)
  • [8] Long Non-coding RNA MIAT Mediates Non-small Cell Lung Cancer Development Through Regulating the miR-128-3p/PELI3 Axis
    Li, Fannian
    Li, Haitao
    Li, Shuai
    Lv, Baolei
    Shi, Junjie
    Yan, Hongjiang
    Zhang, Helin
    He, Yuzheng
    [J]. BIOCHEMICAL GENETICS, 2020, 58 (06) : 867 - 882
  • [9] Exosomes-transmitted miR-7 reverses gefitinib resistance by targeting YAP in non-small-cell lung cancer
    Chen, Rui
    Qian, Zijun
    Xu, Xin
    Zhang, Congcong
    Niu, Yongjie
    Wang, Zhixian
    Sun, Jianli
    Zhang, Xiao
    Yu, Yongchun
    [J]. PHARMACOLOGICAL RESEARCH, 2021, 165
  • [10] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Kobayashi, S
    Boggon, TJ
    Dayaram, T
    Janne, PA
    Kocher, O
    Meyerson, M
    Johnson, BE
    Eck, MJ
    Tenen, DG
    Halmos, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08): : 786 - 792
12345